-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
CRISPR Therapeutics AG quarterly/annual Operating Income (Loss) history and growth rate from 2014 to 2023.
- CRISPR Therapeutics AG Operating Income (Loss) for the quarter ending June 30, 2024 was -$151M, a 58.8% decline year-over-year.
- CRISPR Therapeutics AG Operating Income (Loss) for the twelve months ending June 30, 2024 was -$355M, a 25.1% increase year-over-year.
- CRISPR Therapeutics AG annual Operating Income (Loss) for 2023 was -$223M, a 66.9% increase from 2022.
- CRISPR Therapeutics AG annual Operating Income (Loss) for 2022 was -$673M, a 280% decline from 2021.
- CRISPR Therapeutics AG annual Operating Income (Loss) for 2021 was $374M.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)